Lipella Pharmaceuticals INC 8-K filings
OTC.Pink
Lipella Pharmaceuticals has set September 10, 2024, for its annual shareholder meeting and established deadlines for submitting shareholder proposals and director nominations.
OTC.Pink
Lipella Pharmaceuticals has closed a $1.28 million registered direct offering priced at-the-market under Nasdaq rules.
OTC.Pink
Lipella Pharmaceuticals has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, giving them until October 14, 2024, to regain compliance.
OTC.Pink
8-K: Lipella Pharmaceuticals Eliminates Series A Preferred Stock Following Conversion to Common Shares
Lipella Pharmaceuticals has eliminated its Series A preferred stock, converting all outstanding shares to common stock.
OTC.Pink
Lipella Pharmaceuticals' CEO and Chief Medical Officer each purchased $100,000 of the company's common stock at the market price of $0.6901 per share.